缬沙坦对降血压和保护肾脏的作用研究

目的 观察血管紧张素Ⅱ受体拮抗剂(ARB)缬沙坦对原发性高血压伴早期糖尿病肾病患者的降压效果和肾脏保护作用.方法 轻、中度原发性高血压伴早期糖尿病肾病患者100例随机分为缬沙坦组和美托洛尔加氢氯噻嗪组各50例.根据血压调整剂量和疗程,6个月后对两组血压及24h尿白蛋白排泄率进行对比.结果 两组的降压及副作用差异无统计学意义(P0.05).缬沙坦组和美托洛尔加氢氯噻嗪组在治疗后24h尿白蛋白排泄率(24hUAER)水平和24hUAER的降低幅度方面比较差异有统计学意义(均P<0.05),其余指标差异无统计学意义(P0.05).结论 缬沙坦治疗轻、中度原发性高血压的有效率和美托洛尔加氢氯噻嗪近似且耐受性好,可以减慢早期糖尿病肾病的进展而具有肾脏保护作用.

Study on the antihypertensive and renoprotective effects of valsartan

Objective To observe the efffects of angiotensin Ⅱ receptor antagonist (ARB) valsartan in decreasing blood pressure and protecting kidney to the patients suffering from mild-or-moderate hypertension companied with earlier type 2 diabetic nephropathy. Methods The patients suffering from mild-to-moderate hypertension and earlier type 2 diabetic nephropathy were divided into two groups. One of the groups were treated by valsartan, and the other were treated by betaloc and aldadinc. The period of the treatment and doses of the medicines were adjusted depending on the blood pressure 4 weeks later. The therapeutic effects of the two medicines were analyzed 6 months later. Results There was no difference in the effects of decreasing blood pressure and side-effects between the two groups. There are marked discrepancy between the two groups in the post-trearment 24h urinary albumin excretion rate (UAER) and the variation of 24h UAER (all P<0.05). There was no significant difference in others parameters (all P0.05). Conclusion Valsartan could prevent early proteinuria of type 2 diabetic nephropathy from developping and protect the function of kidney.